BRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease

Reuters10-27

BRIEF-<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease

Oct 27 (Reuters) - Hoth Therapeutics Inc HOTH.O:

HOTH THERAPEUTICS LAUNCHES VA-BACKED STUDY OF NOVEL GDNF WEIGHT LOSS THERAPY TARGETING OBESITY AND FATTY LIVER DISEASE
HOTH THERAPEUTICS INC - INITIAL RESULTS EXPECTED Q1 2026

Source text: ID:nPn5FdV4Ma

Further company coverage: HOTH.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2578641795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578641795","market":"us","top_or_hot":-1,"title":"BRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease</title></head><body><p><span>Oct 27 (Reuters)</span><span> - </span>Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>HOTH.O</span>:</p><ul><li><p>HOTH THERAPEUTICS LAUNCHES VA-BACKED STUDY OF NOVEL GDNF WEIGHT LOSS THERAPY TARGETING OBESITY AND FATTY LIVER DISEASE</p></li><li><p>HOTH THERAPEUTICS INC - INITIAL RESULTS EXPECTED Q1 2026</p></li></ul><p>Source text: <span>ID:nPn5FdV4Ma</span></p><p>Further company coverage: <span>HOTH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-27 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease</title></head><body><p><span>Oct 27 (Reuters)</span><span> - </span>Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>HOTH.O</span>:</p><ul><li><p>HOTH THERAPEUTICS LAUNCHES VA-BACKED STUDY OF NOVEL GDNF WEIGHT LOSS THERAPY TARGETING OBESITY AND FATTY LIVER DISEASE</p></li><li><p>HOTH THERAPEUTICS INC - INITIAL RESULTS EXPECTED Q1 2026</p></li></ul><p>Source text: <span>ID:nPn5FdV4Ma</span></p><p>Further company coverage: <span>HOTH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nFWN3W81GW:1","article_id":"2578641795","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578641795","pubTimestamp":1761570980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver DiseaseOct 27 (Reuters) - Hoth Therapeutics Inc HOTH.O:HOTH THERAPEUTICS LAUNCHES V","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HOTH":"Hoth Therapeutics"},"translate_title":"BRIEF-Hoth Therapeutics启动VA支持的针对肥胖和脂肪肝病的新型GDNF减肥疗法研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":0.9},"content_text":"BRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver DiseaseOct 27 (Reuters) - Hoth Therapeutics Inc HOTH.O:HOTH THERAPEUTICS LAUNCHES VA-BACKED STUDY OF NOVEL GDNF WEIGHT LOSS THERAPY TARGETING OBESITY AND FATTY LIVER DISEASEHOTH THERAPEUTICS INC - INITIAL RESULTS EXPECTED Q1 2026Source text: ID:nPn5FdV4MaFurther company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578641795","isCrawlerRequest":true}